Background: Antibiotics play an important role in the treatment of infections to the humans and at the same time, irrational, frequent prescription of higher antibiotics, change in gene composition of microorganisms are all the reasons behind the development and introduction of new antibiotics against different microorganisms.
Objective: In this project, an attempt has been made to synthesize some derivatives of diazenyl containing phenyl styryl ketones and also their in vitro screening was conducted against Mycobacterium tuberculosis, Escherichia coli, Klebsiella pneumonia, Bacillus subtilis, Staphylococcus aureus, Aspergillus niger and Candida albicans.
Methods: Ten molecules were synthesized which are diazenyl containing chalcones. 4- aminoacetophenone was diazotised and piperidine was coupled with the formed diazonium chloride. Further, the acetoxy group underwent Claisen-Schmidt condensation with differently substituted aldehydes to form the final compounds- the chalcones. The proposed chemical structures were confirmed by different spectroscopic techniques like FTIR, 1H NMR and Mass spectroscopy. TLC was used to know that the reactants were exhausted and the formation of the product occurred. Sharp melting point of the compounds concludes the purity.
Results: The MIC of the compounds 3CP, 3DP, 3EP and 3GP is 20 times the MIC of the standard fluconazole drug against Aspergillus niger. The compound 3GP is as equipotent as the standard drug Pyrazinamide with MIC of 3.12 µg/ml against Mycobacterium tuberculosis.
Conclusion: The results are quite promising which on further studies may lead to drug molecules against different microorganisms. Especially, 3EP can be considered as a broad spectrum agent due to its potent activity against different microorganisms like Staphylococcus aureus, Escherichia coli, Klebsiella pneumonia and Candida albicans.
Keywords: Diazenyl styryl chalcones, antimicrobial, antifungal, piperidine, claisen-schmidt, pyrazinamide.
Structure-Activity Relationships of Pyrrole Hydrazones as New Anti-Tuberculosis Agents
Medicinal Chemistry Pregnane X Receptor (PXR) at the Crossroads of Human Metabolism and Disease
Current Drug Metabolism Towards the Design and Development of Agents with Broad Spectrum Chemotherapeutic Properties for the Effective Treatment of HIV / AIDS
Current Medicinal Chemistry Adjunctive Immunotherapy of Mycobacterial Infections
Current Pharmaceutical Design Pulmonary Sarcoidosis Presenting with Miliary Opacities
Current Medical Imaging Editorial from Guest Editor (Thematic Issue: Tuberculosis: Recent Advances in Our Understanding and Management)
Current Respiratory Medicine Reviews Medicinal Botanicals in the Traditional Medicine of the Veps Used for Bronchial Infections
Current Traditional Medicine Does the Development of Vaccines Advance Solutions for Tuberculosis?
Current Molecular Pharmacology New Frontiers in the Therapy of Tuberculosis: Fighting with the Global Menace
Mini-Reviews in Medicinal Chemistry New Tuberculostatic Agents Targeting Nucleic Acid Biosynthesis: Drug Design using QSAR Approaches
Current Pharmaceutical Design Nano-Based Anti-Tubercular Drug Delivery and Therapeutic Interventions in Tuberculosis
Current Drug Targets Iron Regulation in Tuberculosis Research: Promise and Challenges
Current Medicinal Chemistry A Review of Recent Advancements in Anti-tubercular Molecular Hybrids
Current Medicinal Chemistry Antitubercular Natural Terpenoids: Recent Developments and Syntheses
Current Organic Synthesis Liposomes as Potential Carrier System for Targeted Delivery of Polyene Antibiotics
Recent Patents on Inflammation & Allergy Drug Discovery Itraconazole Induced Congestive Heart Failure, A Case Study
Current Drug Safety The Immunopathology of Tuberculosis – An Update
Current Respiratory Medicine Reviews Pyrrole-Based Hydrazones Synthesized and Evaluated In Vitro as Potential Tuberculostatics
Letters in Drug Design & Discovery Molecular Modeling Databases: A New Way in the Search of Protein Targets for Drug Development
Current Bioinformatics Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach
Current Pharmaceutical Design